UBS Asset Management Americas Inc. held its stake in Imperva Inc. (NYSE:IMPV) during the third quarter, Holdings Channel reports. The fund owned 13,939 shares of the company’s stock at the end of the third quarter. UBS Asset Management Americas Inc.’s holdings in Imperva were worth $749,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in IMPV. Robeco Institutional Asset Management B.V. boosted its stake in Imperva by 20.0% in the second quarter. Robeco Institutional Asset Management B.V. now owns 30,000 shares of the company’s stock valued at $1,290,000 after buying an additional 5,000 shares during the last quarter. Artemis Investment Management LLP acquired a new stake in Imperva during the second quarter valued at $398,000. Kornitzer Capital Management Inc. KS boosted its stake in Imperva by 31.9% in the second quarter. Kornitzer Capital Management Inc. KS now owns 589,560 shares of the company’s stock valued at $25,357,000 after buying an additional 142,700 shares during the last quarter. Emerald Acquisition Ltd. acquired a new stake in Imperva during the second quarter valued at $3,732,000. Finally, State Board of Administration of Florida Retirement System boosted its position in shares of Imperva by 1.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 17,640 shares of the company’s stock worth $759,000 after buying an additional 277 shares in the last quarter. 92.72% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Imperva Inc. (NYSE:IMPV) remained flat at $40.35 on Thursday. 440,578 shares of the company’s stock were exchanged. Imperva Inc. has a 1-year low of $31.11 and a 1-year high of $57.93. The stock’s market capitalization is $1.33 billion. The stock has a 50 day moving average of $38.37 and a 200-day moving average of $43.19.
Imperva (NYSE:IMPV) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.24. Imperva had a negative return on equity of 28.37% and a negative net margin of 25.60%. The business had revenue of $68.40 million for the quarter, compared to the consensus estimate of $63.10 million. During the same period in the prior year, the business posted $0.19 earnings per share. The company’s quarterly revenue was up 8.0% compared to the same quarter last year. On average, analysts predict that Imperva Inc. will post ($0.37) EPS for the current year.
A number of equities analysts recently weighed in on IMPV shares. Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $60.00 price objective on shares of Imperva in a report on Friday, September 23rd. JMP Securities reissued an “outperform” rating and set a $56.00 price objective (up from $50.00) on shares of Imperva in a report on Sunday, September 25th. Nomura cut Imperva from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Monday, September 26th. Buckingham Research cut Imperva from a “buy” rating to a “neutral” rating in a report on Thursday, September 29th. Finally, BTIG Research cut Imperva from a “buy” rating to a “neutral” rating in a report on Monday, October 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $49.50.
In other news, insider Amichai Shulman sold 3,085 shares of the stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $40.10, for a total value of $123,708.50. Following the sale, the insider now directly owns 92,000 shares in the company, valued at $3,689,200. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Mark E. Kraynak sold 3,332 shares of the stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $40.16, for a total value of $133,813.12. Following the completion of the sale, the senior vice president now owns 448 shares in the company, valued at $17,991.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,587 shares of company stock worth $506,173. Company insiders own 2.20% of the company’s stock.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.
Want to see what other hedge funds are holding IMPV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imperva Inc. (NYSE:IMPV).